Percutaneous mitomycin C perfusion of bilateral ureteral carcinoma in situ.
We treated a 61-year-old patient with a diagnosis of bilateral ureteral carcinoma in situ with percutaneous perfusions of mitomycin C. After 16 sessions of mitomycin C therapy instilled through bilateral nephrostomy tubes, the urine cytology results became negative for malignancy. Bilateral ureteroscopy and cold-cup punch biopsies of the ureter revealed no evidence of disease. The patient did not experience side effects. He has remained free of disease during a 12-month follow-up period. Percutaneous perfusion of mitomycin C appears to be one of the effective and safe treatments for the carcinoma in situ of the upper urinary tract.
Amano
T
T
Department of Urology, Kanazawa, University School of Medicine, Japan.
Naito
K
K
Koshida
K
K
Kunimi
K
K
Morishita
H
H
Hisazumi
H
H
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002278:Carcinoma in Situ / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage* / Q000627:therapeutic use; D009403:Nephrostomy, Percutaneous; D013997:Time Factors; D014516:Ureteral Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
D016685:Mitomycin; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate